NASDAQ:BCEL

Atreca Competitors

$11.77
+0.36 (+3.16 %)
(As of 04/21/2021 02:15 PM ET)
Add
Compare
Today's Range
$11.38
Now: $11.77
$11.78
50-Day Range
$11.45
MA: $15.00
$18.46
52-Week Range
$11.01
Now: $11.77
$25.03
Volume1,902 shs
Average Volume257,717 shs
Market Capitalization$433.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08

Competitors

Atreca (NASDAQ:BCEL) Vs. HRTX, SUPN, MYOV, ADCT, HRMY, and PRLD

Should you be buying BCEL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Atreca, including Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Myovant Sciences (MYOV), ADC Therapeutics (ADCT), Harmony Biosciences (HRMY), and Prelude Therapeutics (PRLD).

Heron Therapeutics (NASDAQ:HRTX) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares Heron Therapeutics and Atreca's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Heron Therapeutics-216.18%-65.06%-49.14%
AtrecaN/A-43.21%-40.98%

Institutional and Insider Ownership

99.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 69.6% of Atreca shares are owned by institutional investors. 12.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 9.9% of Atreca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Heron Therapeutics and Atreca's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$145.97 million11.31$-204,750,000.00($2.50)-7.23
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76

Atreca has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Heron Therapeutics and Atreca, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Heron Therapeutics01402.80
Atreca00503.00

Heron Therapeutics presently has a consensus target price of $26.00, indicating a potential upside of 44.52%. Atreca has a consensus target price of $28.75, indicating a potential upside of 145.31%. Given Atreca's stronger consensus rating and higher possible upside, analysts plainly believe Atreca is more favorable than Heron Therapeutics.

Risk & Volatility

Heron Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Atreca has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Summary

Atreca beats Heron Therapeutics on 8 of the 13 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Supernus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtrecaN/A-43.21%-40.98%
Supernus Pharmaceuticals27.09%20.02%9.67%

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 96.1% of Supernus Pharmaceuticals shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Comparatively, 6.6% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Supernus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76
Supernus Pharmaceuticals$392.76 million4.24$113.06 million$2.1015.00

Supernus Pharmaceuticals has higher revenue and earnings than Atreca. Atreca is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Supernus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atreca00503.00
Supernus Pharmaceuticals00203.00

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Supernus Pharmaceuticals has a consensus price target of $37.50, indicating a potential upside of 18.93%. Given Atreca's higher probable upside, equities research analysts plainly believe Atreca is more favorable than Supernus Pharmaceuticals.

Volatility and Risk

Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.

Summary

Supernus Pharmaceuticals beats Atreca on 9 of the 12 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Myovant Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtrecaN/A-43.21%-40.98%
Myovant SciencesN/AN/A-201.20%

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 33.8% of Myovant Sciences shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Myovant Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-5.64

Myovant Sciences is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Myovant Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atreca00503.00
Myovant Sciences03302.50

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Myovant Sciences has a consensus price target of $31.1667, indicating a potential upside of 64.21%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than Myovant Sciences.

Volatility and Risk

Atreca has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.99, indicating that its stock price is 199% more volatile than the S&P 500.

Summary

Atreca beats Myovant Sciences on 8 of the 11 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtrecaN/A-43.21%-40.98%
ADC TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and ADC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76
ADC Therapeutics$2.34 million696.57$-116,480,000.00($2.36)-10.03

Atreca has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and ADC Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atreca00503.00
ADC Therapeutics01402.80

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. ADC Therapeutics has a consensus price target of $47.50, indicating a potential upside of 103.34%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than ADC Therapeutics.

Summary

Atreca beats ADC Therapeutics on 7 of the 11 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtrecaN/A-43.21%-40.98%
Harmony BiosciencesN/AN/AN/A

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Harmony Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76
Harmony BiosciencesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Harmony Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atreca00503.00
Harmony Biosciences00303.00

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Harmony Biosciences has a consensus price target of $51.6667, indicating a potential upside of 84.52%. Given Atreca's higher probable upside, equities research analysts plainly believe Atreca is more favorable than Harmony Biosciences.

Summary

Atreca beats Harmony Biosciences on 4 of the 6 factors compared between the two stocks.

Atreca (NASDAQ:BCEL) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Profitability

This table compares Atreca and Prelude Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtrecaN/A-43.21%-40.98%
Prelude TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

69.6% of Atreca shares are owned by institutional investors. Comparatively, 76.2% of Prelude Therapeutics shares are owned by institutional investors. 9.9% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atreca and Prelude Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtrecaN/AN/A$-67,480,000.00($4.26)-2.76
Prelude TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Atreca and Prelude Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atreca00503.00
Prelude Therapeutics03102.25

Atreca currently has a consensus price target of $28.75, indicating a potential upside of 145.31%. Prelude Therapeutics has a consensus price target of $54.25, indicating a potential upside of 52.22%. Given Atreca's stronger consensus rating and higher probable upside, equities research analysts plainly believe Atreca is more favorable than Prelude Therapeutics.

Summary

Atreca beats Prelude Therapeutics on 4 of the 7 factors compared between the two stocks.


Atreca Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.07+1.6%$1.63 billion$145.97 million-7.32
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49+2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$19.02+6.1%$1.62 billionN/A-6.77Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.66+2.9%$1.58 billion$2.34 million-10.03
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82+1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.91+7.5%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.87+2.5%$1.52 billion$175.34 million-15.22Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.30+3.5%$1.51 billion$320,000.00-8.37
uniQure logo
QURE
uniQure
1.7$32.19+1.0%$1.46 billion$7.28 million-8.54Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.50+2.4%$1.46 billion$82.27 million-18.29
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.65+3.3%$1.44 billionN/A-3.21Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$62.28+1.7%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.17+0.4%$1.42 billion$73.41 million-4.69News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.64+2.2%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.21+5.9%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89+0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.27+2.8%$1.37 billion$19.89 million-13.33
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.40+3.4%$1.37 billion$4.23 million-20.30Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$35.52+5.5%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.78+2.6%$1.30 billion$2.91 billion-8.50
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.64+7.2%$1.28 billionN/A-144.33Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.61+0.3%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.64+4.1%$1.22 billion$29.54 million-7.33News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.11+1.1%$1.21 billion$261.02 million6.18News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$33.26+2.9%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.33+1.9%$1.18 billionN/A0.00Analyst Report
Insider Selling
News Coverage
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.50+3.2%$1.17 billion$230,000.00-12.79
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.91+4.5%$1.16 billion$59.70 million-199.10
Omeros logo
OMER
Omeros
1.2$19.27+3.7%$1.15 billion$111.81 million-8.10
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$31.01+0.5%$1.14 billionN/A-17.23
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.40+1.1%$1.14 billionN/A-8.89Analyst Report
Increase in Short Interest
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$21.38+6.1%$1.13 billionN/A0.00Insider Selling
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.37+3.8%$1.12 billion$4.23 million-8.59
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.95+1.5%$1.11 billionN/A-2.57
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.22+0.7%$1.10 billionN/A-6.84Upcoming Earnings
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.23+2.0%$1.10 billion$42.12 million-12.02
MannKind logo
MNKD
MannKind
1.4$4.50+6.0%$1.05 billion$63.04 million-21.43Increase in Short Interest
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$18.92+0.6%$1.05 billion$3.65 million-1.99
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.14+2.4%$1.03 billionN/A-8.17
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.91+1.6%$1.03 billion$122.47 million-28.52
NKTX
Nkarta
1.8$33.67+7.2%$1.02 billionN/A0.00
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.19+0.9%$1.02 billionN/A-6.64
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.18+2.6%$1.01 billion$35.22 million-6.70
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$29.61+4.8%$1.01 billion$57.05 million0.00Analyst Report
News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.7$25.31+1.8%$1.01 billion$800.40 million23.88
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$28.70+9.5%$1.00 billionN/A0.00
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.83+0.1%$969.04 millionN/A-12.82
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.46+2.2%$962.90 million$20.79 million-12.92
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.70+0.1%$951.21 millionN/A-7.83Gap Up
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.47+2.5%$950.88 million$120,000.00-3.51Analyst Report
News Coverage
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.